Basket Study Yields Approval for Rare Cancer [News in Brief]

The FDA, in a regulatory first, approved a targeted therapy based on a basket study. The move, which expanded the indications for the BRAF inhibitor vemurafenib to include Erdheim–Chester disease, points to a new approval pathway for drugs that treat rare cancers.

from Cancer via ola Kala on Inoreader http://ift.tt/2CPf6DR
via IFTTT